Antifungal Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 244 of the 250 references it cites were found in a registry or an index.
Abstract
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This has been attributed to non-mycologic causes such as host factors, immune status, and/or pharmacologic issues8.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
In the citing paper
“it leaves the polyene amphotericin B, which is toxic8, as the only treatment option for these infections.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · cited 2×
“…of cryptococcal meningitis 14 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg (Perfect et al. 2010), and, until recently, although clinical efficacy was clear with this strategy, formal PK/PD studies were lacking for this…”
BackgroundRex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,556
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“From a pharmacodynamic (PD) perspective, PK measures represent drug exposure with respect to the host, for example, translating a dose (i.e., mg/kg) to a drug exposure (e.g., area under the concentration curve, or AUC) (Drusano 2004).”
BackgroundPascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 1×
“Study from two phase 3 clinical trials of micafungin use in patients with candidemia or invasive candidiasis was recently used for PK/PD analysis (Andes et al. 2012).”
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241
Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 176
“Readers are referred to excellent reviews on these topics [50,51].”
BackgroundIdentification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 144
“and interact with other drugs such as chemotherapy agents and immunosuppressants (4).”
BackgroundDefining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118
Antifungals: From Pharmacokinetics to Clinical Practice
do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 132
“These combinations could improve the efficacy and the safety of the treatment [46,47,66,143].”
BackgroundInfluentialLepak, A. J., Zhao, M., VanScoy, B. D., Taylor, D. S., Ellis‐Grosse, E. J., Ambrose, P. G., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-17 · Cited by 102
Self-citationPharmacodynamic Optimization for Treatment of Invasive Candida auris Infection
Lepak, A. J., Zhao, M., Berkow, E. L., Lockhart, S. R., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-17 · Cited by 89
“Specifically, AUC/MIC (area under the concentration-time curve over 24 h in the steady state divided by the MIC) was used for fluconazole and micafungin, and Cmax/MIC (the maximum concentration of drug in serum divided by the MIC) was used for amphotericin B (26, 27).”
BackgroundMethodInfluentialSelf-citationDrug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
Rayner, C. R., Smith, P. F., Andes, D. R., Andrews, K. A., Derendorf, H., Friberg, L. E., Hanna, D. L., Lepak, A. J., Mills, E. J., Polasek, T. M., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2198 · Cited by 84
“Common PK/PD studies in the model include dose fractionation, time kill, and multi- organism escalating drug exposure.(87) The exposureresponse analysis for each of these study designs helps to inform important aspects about a drug’s activity, including a PK/PD index that drives efficacy (e.”
Self-citationLepak, A. J., Zhao, M., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01572-18 · Cited by 79
“As in other echinocandin studies, the PK/PD index AUC/MIC strongly predicted efficacy.”
MethodSelf-citationKaindl, T., Andes, D. R., Engelhardt, M. F., Saulay, M., Larger, P. J., & Groll, A. H. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky463 · Cited by 80
Self-citationRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids
Lazzarini, C., Haranahalli, K., Rieger, R. A., Ananthula, H. K., Desai, P. B., Ashbaugh, A., Linke, M. J., Cushion, M. T., Ruzsicska, B. P., Haley, J. D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00156-18 · Cited by 73
Veloso, D. F. M. C., Benedetti, N. I. G. M., Ávila, R. I., Bastos, T. S. A., Silva, T. C., Silva, M. R. R., Batista, A. C., Valadares, M. C., & Lima, E. M. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1492046 · Cited by 69
“In clinical trials using azole antimicrobials for the treatment of invasive candidiasis, when this AUC/MIC ratio is >25, treatment success is at least 91% (Lepak & Andes, 2014).”
BackgroundWiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71
“In mouse PK-PD studies, a net stasis outcome (lack of change in burden over the treatment period) has been correlated with clinical efficacy in humans, especially for the echinocandins (44).”
ResultAntifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives
Branda, F., Petrosillo, N., Ceccarelli, G., Giovanetti, M., VITO, A. D., Madeddu, G., Scarpa, F., & Ciccozzi, M. (2025) · Infectious Disease Reports · doi:10.3390/idr17040091 · Cited by 84
“…correlate with clinical or microbiological outcome, in relation to the pathogen’s in vitro susceptibility, usually expressed as Minimum Inhibitory Concentration (MIC), which represents the lowest drug concentration that inhibits visible fungal growth under standardized laboratory conditions [22].”
InfluentialNeofytos, D., García‐Vidal, C., Lamoth, F., Lichtenstern, C., Perrella, A., & Vehreschild, J. J. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05958-3 · Cited by 69
O’Brien, B., Chaturvedi, S., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02195-19 · Cited by 63
“The findings of the present study need further evaluation by pharmacokinetic/ pharmacodynamic studies and testing in animal models to assess their clinical relevance (15, 16).”
BackgroundZhao, Y., Seelhammer, T. G., Barreto, E. F., & Wilson, J. W. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2348 · Cited by 64
Sharma, C., & Kadosh, D. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011190 · Cited by 63
“The immune status of the patient, along with other host factors and pharmacologic issues, including interaction of drug and the fungus, can directly or indirectly affect therapeutic responses [60].”
BackgroundSingh, A., Kumar, J., Sharma, V. K., Singh, D. K., Kumari, P., Nishad, J. H., Gautam, V. S., & Kharwar, R. N. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.03.004 · Cited by 57
Prasath, K. G., Alexpandi, R., Parasuraman, R., Pavithra, M., Ravi, A. V., & Pandian, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111043 · Cited by 57
Na, Y., Huh, H. W., Kim, M., Byeon, J., Han, M.-G., Lee, H.-K., & Cho, C. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.10.024 · Cited by 51
Updated antimicrobial dosing recommendations for obese patients
Castro‐Balado, A., Varela-Rey, I., Mejuto, B., Mondelo‐García, C., Zarra‐Ferro, I., Rodríguez-Jato, T., & Fernández‐Ferreiro, A. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-23 · Cited by 60
“Regarding their PK/PD index, AUC 0-24 /MIC correlates with effectiveness against invasive fungal infections (221).”
BackgroundNext-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 54
“Nevertheless, prolonged exposure to flucytosine may lead to bone marrow suppression, necessitating careful monitoring of hematologic parameters 74 .”
What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?
Chai, M. G., Cotta, M. O., Abdul-Aziz, M. H., & Roberts, J. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070638 · Cited by 51
Overview of antifungal dosing in invasive candidiasis
Pea, F., & Lewis, R. E. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx447 · Cited by 42
Funding and Innovation in Diseases of Neglected Populations: The Paradox of Cryptococcal Meningitis
Rodrigues, M. L. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004429 · Cited by 44
“5-Flucytosine is not widely available outside of resource-rich areas, and it has potential hematologic toxicities that must be monitored closely during medication administration [12].”
BackgroundFeng, Y., Lu, H., Whiteway, M., & Jiang, Y. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.019 · Cited by 40
Lu, W., Pan, M., Ke, H., Liang, J. S., Liang, W., Yu, P., Zhang, P., & Wang, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1044234 · Cited by 41
Haranahalli, K., Lazzarini, C., Sun, Y., Zambito, J., Pathiranage, S., McCarthy, J., Mallamo, J. P., Poeta, M. D., & Ojima, I. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01004 · Cited by 39
Hava, D. L., Tan, L., Johnson, P., Curran, A. K., Perry, J. K., Kramer, S., Kane, K., Bedwell, P., Layton, G. R., Swann, C., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14166 · Cited by 38
Sphingolipids: Regulators of azole drug resistance and fungal pathogenicity
Song, J., Xiao, L., & Li, R. (2020) · Molecular Microbiology · doi:10.1111/mmi.14586 · Cited by 39
“Additionally, some glycophosphatidylinositol (GPI)-anchored proteins play an important role in fungal cell wall synthesis and their deficiency results in cell wall defects (Lesage and Bussey, 2006).”
BackgroundAdministration and Dosing of Systemic Antifungal Agents in Pediatric Patients
Downes, K. J., Fisher, B. T., & Zane, N. R. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00379-2 · Cited by 37
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Liedke, S. C., Zamith‐Miranda, D., Gomes, K. X., Gonçalves, J. L. S., Frasés, S., Nosanchuk, J. D., Rodrigues, M. L., Nimrichter, L., Peralta, J. M., & Guimaraes, A. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-12540-y · Cited by 36
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
Lyster, H. S., Shekar, K., Watt, K., Reed, A. K., Roberts, J. A., & Abdul-Aziz, M. H. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01264-0 · Cited by 38
Lepak, A. J., Zhao, M., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-19 · Cited by 34
Self-citationPereira, L. C., de Fátima, M. A., Santos, V. V., Brandão, C. M., Alves, I. A., & Azeredo, F. J. (2022) · Antibiotics · doi:10.3390/antibiotics11080986 · Cited by 31
“This approach contributes to increased clinical efficacy and reduced adverse effects [71].”
BackgroundLu, H., Li, W., Whiteway, M., Wang, H., Zhu, S., Ji, Z., Feng, Y., Yan, L., Fang, T., Li, L., et al. (2023) · mBio · doi:10.1128/mbio.02639-22 · Cited by 30
“outcome and low levels of clinical resistance is likely to be multifactorial (5), FLC toler-”
BackgroundEgger, M., Bellmann, R., Krause, R., Boyer, J., Jakšić, D., & Hoenigl, M. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s372546 · Cited by 31
“…63 However, the combination of posaconazole and caspofungin resulted in remarkable synergistic efficacy against azole-resistant Aspergillus spp. 68 Even though posaconazole showed better in vitro activity than other azoles against many zygomycetes including Rhizomucor spp. it is less active…”
BackgroundAndes, D. R., Brüggemann, R. J. M., Flanagan, S., Lepak, A. J., Lewis, R. E., Ong, V. S., Rubino, C. M., & Sandison, T. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae415 · Cited by 35
Self-citationBocxlaer, K. V., & Croft, S. L. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00343c · Cited by 26
No Dose Adjustment for Isavuconazole Based on Age or Sex
Desai, A. V., Han, D., Kowalski, D. L., Lademacher, C., Pearlman, H., & Yamazaki, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02629-18 · Cited by 25
“While there have been a number of studies on the PK and pharmacodynamics of 139 other azoles [reviewed elsewhere (4, 14-18)], few have directly investigated the effect of age 140 group or sex.”
BackgroundPopulation pharmacokinetics of rezafungin in patients with fungal infections
Rubino, C. M., & Flanagan, S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-21 · Cited by 22
“A growing body of evidence now suggests standard antifungal dosing may be inadequate for certain patient populations and infections (1, 2).”
BackgroundVariable Sequestration of Antifungals in an Extracorporeal Membrane Oxygenation Circuit
Lyster, H. S., Pitt, T., Maunz, O., Diamond, S., Roberts, J. A., Brown, D. J., Mills, J. J., Armstrong-James, D. P. H., Gerovasili, V., Carby, M. R., et al. (2022) · ASAIO Journal · doi:10.1097/mat.0000000000001802 · Cited by 23
Garvey, E. P., Sharp, J., Warn, P. A., Yates, C. M., Atari, M. I., Thomas, S., & Schotzinger, R. J. (2019) · Medical Mycology · doi:10.1093/mmy/myz092 · Cited by 26
Systemic Antifungal Therapy for Invasive Pulmonary Infections
Ben‐Ami, R. (2023) · Journal of Fungi · doi:10.3390/jof9020144 · Cited by 29
“In vivo drug efficacy correlates with area under the concentration (AUC) curve over the MIC of the target organism (AUC/MIC) [17,18].”
BackgroundIdentification and Elimination of Antifungal Tolerance in Candida auris
Rasouli Koohi, S., Shankarnarayan, S. A., Galon, C. M., & Charlebois, D. A. (2023) · Biomedicines · doi:10.3390/biomedicines11030898 · Cited by 20
“Tolerance, along with host factors, immune status, and pharmacological issues [30], may explain why some patients do not respond to drug therapy despite being infected with fungi that have been determined, by traditional antimicrobial susceptibility testing methods, to be susceptible to a particular drug (i.”
BackgroundJohnson, C., Chen, B., Bhalla, A., Crowell, E. L., & Zhang, F. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125822 · Cited by 19
Preclinical Evaluation of Acylhydrazone SB-AF-1002 as a Novel Broad-Spectrum Antifungal Agent
Lazzarini, C., Haranahalli, K., McCarthy, J., Mallamo, J. P., Ojima, I., & Poeta, M. D. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00946-20 · Cited by 18
“, caspofungin) (10), come with therapeutic challenges, such as nephrotoxicity, drug-drug interactions, a narrow spectrum of activity, and more importantly, emerging resistance (11–14).”
BackgroundSun, N., Xie, Y., Sheng, C., Cao, Y., Zhang, W., Chen, H., & Fan, G. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.020 · Cited by 16
Overcoming Global Antifungal Challenges: Medical and Agricultural Aspects
Galgóczy, L. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00103 · Cited by 17
Jauregizar, N., Quindós, G., Gil-Alonso, S., Suárez, E., Sevillano, E., & Eraso, E. (2022) · Journal of Fungi · doi:10.3390/jof8070727 · Cited by 15
“The PAFE, as a PD characteristic, can influence the dose–response relationships (Fig‐ ure 2) [73,103].”
BackgroundMolla, Y., Roberts, J. A., & Sime, F. B. (2024) · Antibiotics · doi:10.3390/antibiotics13121201 · Cited by 13
Kidd, J. M., Asempa, T. E., & Abdelraouf, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00013-1 · Cited by 14
Kang, H., Uy, J. P., Ho, C. C., Blunt, H. B., Riblet, N. B. V., Pasqualotto, A. C., & Murphy, R. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad472 · Cited by 9
“The pharmacodynamic index most predictive of amphotericin efficacy is the ratio of maximal concentration to minimum inhibitory concentration (Cmax/MIC) [21].”
Beredaki, M.-I., Sanidopoulos, I., Pournaras, S., & Meletiadis, J. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad583 · Cited by 13
“Although AMB is fungicidal, a fungistatic target was the most clinically relevant as also found for echinocandins [22].”
BackgroundShoham, S., Groll, A. H., Petraitis, V., & Walsh, T. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00156-8 · Cited by 16
Extrapolating Antifungal Animal Data to Humans—Is It Reliable?
Stevens, V. M., Mueller, S. W., Reynolds, P., MacLaren, R., & Kiser, T. H. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00370-x · Cited by 12
Sardana, K., Khurana, A., & Singh, A. P. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1675857 · Cited by 13
Current Antifungals and the Developing Pipeline
Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 12
Miltefosine: A Repurposing Drug against Mucorales Pathogens
Xisto, M. I. D. D. S., Rollin‐Pinheiro, R., Rochetti, V. P., de Castro-Almeida, Y., Borba-Santos, L. P., dos Santos, G. M. P., Cypriano, J. B. S., Abreu, F. D. Á., Rozental, S., & Barreto‐Bergter, E. (2023) · Journal of Fungi · doi:10.3390/jof9121166 · Cited by 12
Petraitienė, R., Petraitis, V., Zaw, M., Hussain, K., Arbona, R. J. R., Roilides, E., & Walsh, T. J. (2024) · Journal of Fungi · doi:10.3390/jof10040293 · Cited by 11
A rapid and robust UHPLC-DAD method for the quantification of amphotericin B in human plasma
Barco, S., Zunino, A., D’Avolio, A., Barbagallo, L., Maffia, A., Tripodi, G., Castagnola, E., & Cangemi, G. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.01.048 · Cited by 11
Meletiadis, J., Beredaki, M.-I., Elefanti, A., Pournaras, S., & Muller, A. E. (2023) · Journal of Fungi · doi:10.3390/jof9040434 · Cited by 10
“A 50% of maximal effect and stasis were proposed for triazoles and echinocandins, respectively [22].”
BackgroundASTRO-CM Study Team, Alhadab, A. A., Rhein, J., Tugume, L., Musubire, A. K., Williams, D. A., Abassi, M., Nicol, M. R., Meya, D. B., Boulware, D. R., et al. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09657-0 · Cited by 9
“blood–brain barrier and fungal cell wall), bind to therapeutic targets, and elicit pharmacological action [37].”
BackgroundYasinskaya, Y., Bala, S., Waack, U., Dixon, C., Higgins, K., Moore, J. N., Jjingo, C. J., O’Shaughnessy, E. M., Colangelo, P. M., Botgros, R., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad195 · Cited by 10
SAR study of N′-(Salicylidene)heteroarenecarbohydrazides as promising antifungal agents
Sun, Y., Kim, S., Shin, S., Takemura, K., Matos, G. S., Lazzarini, C., Haranahalli, K., Zambito, J., Garg, A., Poeta, M. D., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117610 · Cited by 9
Tortora, F., Giudici, L. D., Simeoli, R., Chiusolo, F., Cairoli, S., Bernaschi, P., Bianchi, R., Picardo, S. G., Dionisi‐Vici, C., & Goffredo, B. M. (2022) · Antibiotics · doi:10.3390/antibiotics11050640 · Cited by 8
“For echinocandins, the ideal PK/PD target is the maximal plasma concentration (Cmax)/MIC; meanwhile, for azoles the ratio of area under the curve (AUC) on MIC should be considered as an ideal PK/PD target [5].”
BackgroundVoak, A. A., Harris, A., Coterón, J. M., Angulo‐Barturen, Í., Ferrer, S. B., Croft, S. L., & Seifert, K. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009013 · Cited by 8
“Our data points towards a concentration-dependent (AUC driven) pharmacodynamic effect, which supports dosing strategies associated with the administration of large doses infrequently [28], whereby choice of dose and dosing regimens in humans needs to be balanced against tolerability and rate of adverse drug reactions.”
BackgroundInsights into the role of sphingolipids in antifungal drug resistance
Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Fungal Biology Reviews · doi:10.1016/j.fbr.2023.100342 · Cited by 8
Kontou, A., Agakidou, E., Chatziioannidis, I., Chotas, W., Thomaidou, E., & Sarafidis, K. (2024) · Children · doi:10.3390/children11070871 · Cited by 12
“They possess fungicidal properties against most isolates of Candida ( C. ) ( C. albicans , C. glabrata , C. krusei , C. parapsilosis , and C. tropicalis ) and growth-inhibitory effects against Aspergillus spp. without killing them [116].”
BackgroundDrug Interactions of Antifungal Agents: Clinical Relevance and Implications
Corrêa-Junior, D., Frasés, S., & Araújo, G. R. D. S. (2025) · Current Tropical Medicine Reports · doi:10.1007/s40475-024-00336-w · Cited by 7
“Essentially, it outlines the drug’s journey through the body and the temporal changes in its concentration [11].”
Mechanisms of Drug Resistance in Candida albicans
Sanglard, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_15 · Cited by 11
Wright, T. L., Gjeltema, J. L., Wack, R. F., Woodburn, D. B., & Tell, L. A. (2021) · Journal of Zoo and Wildlife Medicine · doi:10.1638/2020-0161 · Cited by 9
“This ratio is within the range considered to be effective in humans.(21) However, trough serum VCZ concentrations .”
BackgroundLuque, S., Mendoza‐Palomar, N., Aguilera‐Alonso, D., Garrido, B., Miarons, M., Piqueras, A. I., Tévar, E., Arnaiz, E. V., & Fernández-Polo, A. (2024) · Anales de Pediatría · doi:10.1016/j.anpedi.2023.11.016 · Cited by 7
Gil-Alonso, S., Quindós, G., Eraso, E., & Jauregizar, N. (2019) · PubMed Central · Cited by 7
Post-transcriptional control of antifungal resistance in human fungal pathogens
Sharma, C., & Kadosh, D. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080527 · Cited by 6
“Host factors, the immune status of the patient, and pharmacologic issues (drug–fungus interactions) can explain these outcomes, which directly or indirectly affect therapeutic responses (Lepak and Andes 2014).”
BackgroundManagement of invasive candidiasis in the ICU: Challenges and advances (Review)
Elmasry, W. G., ABDELBAKY, A., & Awad, A. H. (2025) · Medicine International · doi:10.3892/mi.2025.278 · Cited by 10
“Although not all antifungals require TDM, it is particularly indicated for agents with narrow therapeutic windows, a high interpatient variability, or concen‑ tration‑dependent toxicities (26,29).”
Dosing Antifungals in Obesity: a Literature Review
Amsden, J. R., & Slain, D. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-0335-3 · Cited by 6
Synthesis and Biological Activities of Some 1,2,4-Triazole Derivatives: A Review
Ameen, D. S. M., Al-Ameedee, M. D., & Khan, A. K. (2022) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v22i3.890 · Cited by 8
Li, P., Wang, X., Li, J., Meng, Z., Li, S., Li, Z., Lu, Y., Ren, H., Lou, Y., Lu, C., et al. (2015) · Scientific Reports · doi:10.1038/srep11906 · Cited by 6
“During the research and development of anticancer agent GLB, the pharmacokinetic profile is needed for understanding the absorption, distribution, metabolism and excretion (ADME) of GLB in vivo 22 .”
A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile Species
Visvanathan, N., Lim, J. Y. A., Chng, H. T., & Xie, S. (2023) · Journal of Fungi · doi:10.3390/jof9080810 · Cited by 5
“Polyenes 4 Concentration dependent Yes Cmax/MIC 1: PAFE describes the effect of the antifungal at exposures above the MIC.”
BackgroundInfluentialNaqvi, S. M. H., Gala, M. Y. N., Muchhala, S., Arumugam, A., Panigrahi, D., Patil, D., Rathod, R., & Mane, A. (2023) · World Journal of Pharmacology · doi:10.5497/wjp.v12.i1.1 · Cited by 6
Luque, S., Mendoza‐Palomar, N., Aguilera‐Alonso, D., Garrido, B., Miarons, M., Piqueras, A. I., Tévar, E., Arnaiz, E. V., & Fernández-Polo, A. (2024) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2024.05.001 · Cited by 4
Tamura, N., Okano, A., Kuroda, T., Niwa, H., Kusano, K., Matsuda, Y., Fukuda, K., Mita, H., & NAGATA, S.-I. (2020) · Veterinary Ophthalmology · doi:10.1111/vop.12764 · Cited by 4
Alsowaida, Y. S., Sulaiman, K. A. A., Mahrous, A. J., Alharbi, A. A., Bifari, N., Alshahrani, W. A., Almangour, T. A., Damfu, N., Banamah, A. A., Raya, R. R. A., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107234 · Cited by 4
Luque, S., Mendoza‐Palomar, N., Aguilera‐Alonso, D., Garrido, B., Miarons, M., Piqueras, A. I., Tévar, E., Arnaiz, E. V., & Fernández-Polo, A. (2024) · Farmacia Hospitalaria · doi:10.1016/j.farma.2024.02.013 · Cited by 4
Greene, R. A., Adams, K. K., Rogers, R., Berard-Collins, C., & Lorenzo, M. P. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa034 · Cited by 4
Cornely, O. A., Bassetti, M., García‐Vidal, C., Hoenigl, M., Maertens, J. A., Martín‐Loeches, I., Mira, J. P., & White, P. L. (2025) · Mycoses · doi:10.1111/myc.70135 · Cited by 4
“For echinocandins, both area under the curve/MIC (AUC/ MIC, total exposure) and maximum serum concentration/MIC ( C max /MIC, peak concentration) are linked to treatment success, with some data suggesting that optimising peak levels may offer an additional benefit [29].”
Tóth, Z., Bozó, A., Kovács, R., Balogh, B., Balázs, B., Forgács, L., Kelentey, B., & Majoros, L. (2022) · Mycopathologia · doi:10.1007/s11046-022-00688-9 · Cited by 3
Beredaki, M.-I., Arendrup, M. C., Andes, D. R., & Meletiadis, J. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad096 · Cited by 3
Self-citationgPKPDviz : A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve
Lu, T., Poon, V., Brooks, L., Velasquez, E. F., Anderson, E., Baron, K. T., Jin, J. Y., & Kågedal, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13096 · Cited by 5
“10 Some exposure metrics that are unique to the infection diseases, including time above minimum inhibitory concentration (MIC), C max /MIC ratio, and AUC/MIC ratio, 52,53 are also under consideration for future implementation.”
BackgroundLuque, S., Mendoza‐Palomar, N., Aguilera‐Alonso, D., Garrido, B., Miarons, M., Piqueras, A. I., Tévar, E., Arnaiz, E. V., & Fernández-Polo, A. (2024) · Farmacia Hospitalaria · doi:10.1016/j.farma.2024.02.012 · Cited by 3
Qi, H., Li, X., Chen, Y., Zhang, X., Meng, Y., Li, C., Feng, H., Zhang, J., & Li, C. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.08.019 · Cited by 3
Antidermatophyte activity and PK/PD of ME1111 in a guinea pig model of tinea corporis
Takei‐Masuda, N., Nagira, Y., Kubota-Ishida, N., Chikada, T., Tabata, Y., & Maebashi, K. (2024) · The Journal of Antibiotics · doi:10.1038/s41429-024-00738-y · Cited by 2
“In the case of deep mycosis, the ratio of the area under the drug concentration-time curve (AUC) to the MIC and the ratio of the maximum drug concentration to MIC have been reported to be associated with therapeutic ef fi cacy against fungal infections [28].”
Duangpraphat, M., Wilson, R. C., Rawson, T. M., Santimaleeworagun, W., Nasomsong, W., Holmes, A. H., & Vasikasin, V. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001268 · Cited by 2
“8,9 To overcome the challenges associated with MIC determination, a novel approach known as mechanism-based modeling has been proposed.”
Metadata
- Authors
- Lepak, A. J., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-11-10
- Volume
- 5
- Issue
- 5
- Pages
- a019653-a019653
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC4448584
- OpenAlex
- W2106743979
- Cited by
- 134
- References
- 250
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 14 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 17 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 2 · 2015: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, pharmacokinetics, pharmacodynamics, pharmacokinetic-pharmacodynamic modeling, polyenes, 5-fluorocytosine, azoles, echinocandins, dosing regimen, susceptibility breakpoints, combination antifungal therapy, drug toxicity
- MeSH terms
- Animals, Antifungal Agents, Disease Models, Animal, Flucytosine, Humans, Mycoses, Polyenes, Rabbits, Triazoles, Mice, Rats, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.